Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 6/2016

01-06-2016 | Other Pain (N Vadivelu and A Kaye, Section Editors)

Drug Formulation Advances in Extended-Release Medications for Pain Control

Authors: Mark R. Jones, Martin J. Carney, Rachel J. Kaye, Amit Prabhakar, Alan D. Kaye

Published in: Current Pain and Headache Reports | Issue 6/2016

Login to get access

Abstract

Prescription opioid abusers frequently tamper with opioid tablets in order to either accelerate the delivery of the euphoria-inducing agent or to alter the route of delivery, such that it may be delivered intranasally or intravenously. As one strategy to combat the opioid epidemic in the USA, drug manufacturers have begun to explore formulations which resist such tampering by abusers. Techniques to prevent tampering consist of physical barriers to crushing, chewing, and drug extraction, or aversive or antagonistic agents, incorporated within the formulation itself. Recent years have seen the development of numerous extended-release opioid agents, which are described in this review. This article provides a comprehensive summary of the pharmacology, benefits, risks, and processes behind the development of currently available extended-release opioid drugs, as well as a glimpse into promising future formulations.
Literature
1.
MacPherson RD. The pharmacological basis of contemporary pain management. Pharmacol Ther. 2000;88(2):163–85.CrossRefPubMed
2.
Smith BH, Elliott AM, Chambers WA, Smith WC, Hannaford PC, Penny K. The impact of chronic pain in the community. Fam Pract. 2001;18(3):292–9.CrossRefPubMed
3.
Manchikanti L, Fellows B, Ailinani H. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13:401–35.PubMed
4.
Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Population Health Manag. 2014;17:372–87.CrossRef
5.
Manchikanti L, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl): S67-116.
6.•
Stanos SP, Bruchenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683–94. Provides useful background information on the reasoning behind the development of tamper-resistant formulations.CrossRefPubMedPubMedCentral
7.
Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11–8.CrossRefPubMed
8.
Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5–13.CrossRefPubMed
9.
Pergolizzi JV, Zampogna G, Taylor R, Raffa RB. Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain. Expert Rev Neurother. 2015;13(3):231–8.CrossRef
10.
Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N. Estimating attractiveness for abuse of a not-yet-marketed “abuse-deterrent” prescription opioid formulation. Pain Med. 2010;11(1):81–91.CrossRefPubMed
11.
Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med. 2011;12(5):755–60.CrossRefPubMed
12.
Roland CL, Setnik B, Cleveland JM, Brown DA. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone. Postgrad Med. 2011;123(4):148–59.CrossRefPubMed
13.
Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag. 2011;7(3):193–202.CrossRefPubMed
14.
Webster LR. PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs. 2007;16(3):359–66.CrossRefPubMed
15.
Ruan X. Reexamine the study on abuse potential of Remoxy®: what was missing? Pain Med. 2013;14(1):159–60.CrossRefPubMed
16.
Setnik B, Roland C, Cleveland J, Webster L. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12:618–31.CrossRefPubMed
17.
Benedek I, Jobes J, Xiang Q, Fiske W. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Design, Dev Ther. 2011;5:455–63.
18.
Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. J Opioid Manag. 2011;7(3):179–92.CrossRefPubMed
19.
Centers for Disease Control and Prevention (CDC). Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse—Tennessee 2012. Morbidity and Mortality Weekly Report (MMWR). 2013;62:1–4.
20.
Kotbi N, Han B, Cheng D, Odom AE. Opana ER induced thrombotic thrombocytopenic purpura. Int Med Case Reports J. 2014; 8:97-98.
21.
MacDonald LE, Onsrud JE, Mullins-Hodgin R. Acute sensorineural hearing loss after abuse of an inhaled, crushed oxymorphone extended-release tablet. Pharmacotherapy. 2015;35:e118–21.CrossRefPubMed
22.
Ridgway D, Sopata M, Burneckis A, Jespersen L, Andersen C. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. J Pain Symptom Manag. 2010;39(4):712–20.CrossRef
23.
Hemmingsen PH, Haahr A, Gunnergaard C, Cardot J. Development of a new type of prolonged release hydrocodone formulation based on Egalet ADPREM technology using in vivo-in vitro correlation. Pharmaceutics. 2011;3(1):73–87.CrossRefPubMedPubMedCentral
24.
Brennan MJ, Stanos S. Strategies to optimize pain management with opioids while minimizing risk of abuse. PM R. 2010;2(6):544–58.CrossRefPubMed
25.
Perrino P, Salvatore C, Apseloff G, Harris S. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin tablets compared with original OcyContin tablets in healthy adults. Clin Drug Investig. 2013;33:441–9.CrossRefPubMedPubMedCentral
26.
Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23:1238–46.CrossRefPubMedPubMedCentral
27.
Larance B, Lintzeris N, Bruno R, Peacock A, Cama E, Ali R, et al. The characteristics of a cohort who tamper with prescribed and diverted opioid medications. J Subst Abuse Treat. 2015;58:51–61.CrossRefPubMed
28.
Peacock A, Degenhardt L, Hordern A, Larance B, Cama E, White N, et al. Methods and predictors of tampering-resistant controlled-release oxycodone formulation. Int J Drug Policy. 2015;26(12):1265–72.CrossRefPubMed
29.
Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry. 2015;72(5):424–30.CrossRefPubMed
30.
Havens JR, Leukefeld CG, DeVaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9–17.CrossRefPubMed
31.
McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. Eysenbach G, ed. J Med Internet Res 2014;16(5).
32.
Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidem Drug Safe. 2013;22:1274–82.CrossRef
33.
Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17(4):279–87.CrossRefPubMed
34.
Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16:2142–51.CrossRefPubMed
35.
Gould HJ, Paul D. Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy. Phamacol Res. 2015;91:99–103.CrossRef
36.
Robinson CY, Rubino CM, Farr SJ. A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. J Opioid Manag. 2015;11(5):405–15.CrossRefPubMed
37.
Melhem MR, Rubino CM, Farr SJ, Robinson CY. Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules. Clin Pharmacokinet. 2013;52(10):907–17.CrossRefPubMed
38.
Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989;251:469–76.PubMed
39.
Ko MC, Terner J, Hursh S, Woods JH, Winger G. Relative reinforcing effects of three opioids with different durations of action. J Pharmacol Exp Ther. 2002;301:698–704.CrossRefPubMed
40.
Nalamachu S, Rauch RL, Hale ME, Florete OG, Robinson CY, Farr SJ. A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain. J Pain Res. 2014;7:699–78.
41.
Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Pain Med. 2014;15(6):975–85.CrossRefPubMed
42.
Argoff C et al. Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate. J Opioid Manag. 2015;11(5):417–24.CrossRefPubMed
43.•
Manchikanti L, Atluri S, Kaye AM, Kaye AD. Hydrocodone bitartrate for chronic pain. Drugs Today (Barc). 2015;51(7):415–27. Comprehensive overview of particularly interesting formulation.CrossRef
44.
45.
Schweighardt AE, Juba KM. Extended-release hydrocodone: the devil in disguise or just misunderstood? Ann Pharmacother. 2014;48(10):1362–5.CrossRefPubMed
46.
Covvey JR. Recent developments toward the safer use of opioids, with a focus on hydrocodone. Res Social Adm Pharm. 2015;11(6):901–8.CrossRefPubMed
47.
Bartoli A, Michna E, He E, Wen W. Efficacy and safety of once-daily, extended release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain. Postgrad Med. 2015;127(1):5–12.CrossRefPubMed
48.
Wen W, Taber L, Lynch SY, He E, Ripa S. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain. J Opioid Manag. 2015;11(4):339–56.CrossRefPubMed
49.
50.
Song EK et al. A prospective multicenter study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naïve cancer patients: results of the Korean South West Oncology Group study. Pain Res Manag. 2015;20(6):293–9.CrossRefPubMedPubMedCentral
51.
Devarakonda K, Vandenbossche J, Richarz U. Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing. Springerplus. 2013;2:625.CrossRefPubMedPubMedCentral
52.
Shin SH et al. Clinical usefulness of hydromorphone-OROS in improving sleep disturbances in Korean cancer patients: a multicenter, prospective, open-label study. Cancer Res Treat. 2014;48(4):331–8.CrossRef
53.
Nalamachu S, Ruck D, Nalamasu R, Fasbinder S, Bansal R. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain. J Opioid Manag. 2013;9(1):43–9.CrossRefPubMed
54.
Hale ME, Nalamachu SR, Khan A, Kutch M. Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS hydromorphone extended release in opioid-tolerant patients with chronic low back pain. J Pain Res. 2013;6:319–29.CrossRefPubMedPubMedCentral
55.
Richarz U, Waechter S, Sabatowski R, Szczepanski L, Binsfeld H. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. Pain Pract. 2013;13(1):30–40.CrossRefPubMed
56.
Vandenbossche J, Richarz U, Richards HM. Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS hydromorphone ER) in patients with chronic pain. J Pain Res. 2012;5:523–33.CrossRefPubMedPubMedCentral
57.
Nalamachu SR, Kutch M, Hale ME. Safety and tolerability of once-daily OROS hydromorphone extended-release in opioid tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies. J Pain Smptom Manag. 2012;44(6):852–65.CrossRef
58.
Bannawarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs. 2012;72(13):1713–23.CrossRef
59.
Raffa RB, Pergolizzi Jr JV. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70(13):1657–75.CrossRefPubMed
60.
Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend. 2014;138:1–6.CrossRefPubMed
61.
Schoedel K, Rolleri R, Faulknor J, Pixton G, Chen B, Bass A, et al. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCL (Oxecta) tablets in nondependent recreational opioid users. J Opioid Manag. 2012;8(5):315–27.CrossRefPubMed
62.
Leibowitz M, Zamora C, Brzeczko A, Stark J. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions. Am J Ther. 2014;21(2):99–105.CrossRefPubMed
63.
Smith HS. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. Expert Opin Pharmacother. 2011;12(7):1111–25.CrossRefPubMed
64.
Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year. J Opioid Manag. 2012;8(2):115–25.CrossRefPubMed
65.
Jang DH, Rohe JC, Hoffman RS, Nelson LS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med. 2010;55(3):303–4.CrossRefPubMed
66.
Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6(4):300–3.CrossRefPubMed
67.
Laffont CM, Gomeni R, Heidbreder C, Jones JP, and Nasser AF. Population pharmacokinetic modelling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder. J Clin Pharmacol. 2015. doi:10.​1002/​jcph.​665.
68.
Nassar AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK. A population pharmacokinetic and pharmacodynamics modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet. 2014;53(9):813–24.CrossRef
69.
Nasser et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2015; 36(1):18-26.
Metadata
Title
Drug Formulation Advances in Extended-Release Medications for Pain Control
Authors
Mark R. Jones
Martin J. Carney
Rachel J. Kaye
Amit Prabhakar
Alan D. Kaye
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 6/2016
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-016-0565-9

Other articles of this Issue 6/2016

Current Pain and Headache Reports 6/2016 Go to the issue

Psychological and Behavioral Aspects of Headache and Pain (D Buse, Section Editor)

The Role of Resilience in the Clinical Management of Chronic Pain

Concussion and Head Injury (T Seifert, Section Editor)

The Pathophysiology of Concussion

Secondary Headache (M Robbins, Section Editor)

Post-Traumatic Headache Therapy in the Athlete

Concussion and Head Injury (T Seifert, Section Editor)

Neuropsychological Assessment Following Concussion: an Evidence‐Based Review of the Role of Neuropsychological Assessment Pre- and Post-Concussion

Concussion and Head Injury (T Seifert, Section Editor)

A Historical Perspective on Sports Concussion: Where We Have Been and Where We Are Going

Concussion and Head Injury (T Seifert, Section Editor)

Interventional Treatment for Post-traumatic Headache